Pharmsintez's RAS loss for 2023 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 8% to ₽284.4 million from ₽309.09 million a year earlier.

Pharmsintez sold the Estonian plant Kevelt. The buyer was Dmitry Genkin, Chairman of the Board of Directors of the company. Transactions amounted to €224.8 thousand. At the same time, the parties entered into an option, according to which Pharmsintez has the right to buy back the shares within ten years. Companies also offset the counterclaims on the debt of...

Board of Directors of Pharmsintez convened a meeting of shareholders to resolve the issue of increasing the authorized capital by placing additional shares by public subscription. Meeting will be held on December 21.

Board of Directors of Pharmsintez on November 17 will consider the issue of increasing the authorized capital by placing additional shares by public subscription.